| Identification | Back Directory | [Name]
5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine | [CAS]
40045-50-9 | [Synonyms]
SU 3327
Halicin
JNK Inhibitor XIII - CAS 40045-50-9 - Calbiochem
5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine
5-((5-Nitrothiazol-2-yl)thio)-1,3,4-thiadiazol-2-amine
2-Amino-5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazole
1,3,4-Thiadiazol-2-amine, 5-[(5-nitro-2-thiazolyl)thio]-
5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
JNK,Thiadiazole,SU-3327,TNF-α,Inhibitor,inhibit,SU 3327,p38α,SU3327,insulin,phosphorylation,substrate-competitive,JIP,protein-protein,PPI | [Molecular Formula]
C5H3N5O2S3 | [MDL Number]
MFCD01927019 | [MOL File]
40045-50-9.mol | [Molecular Weight]
261 |
| Chemical Properties | Back Directory | [Melting point ]
160 °C(dec.) | [Boiling point ]
549.8±42.0 °C(Predicted) | [density ]
1.88±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO : 62.5 mg/mL (239.19 mM; Need ultrasonic) | [form ]
Pale yellow solid | [pka]
0.65±0.10(Predicted) | [color ]
Light yellow to Amber to Dark green | [InChI]
InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8) | [InChIKey]
NQQBNZBOOHHVQP-UHFFFAOYSA-N | [SMILES]
S1C(SC2=NC=C([N+]([O-])=O)S2)=NN=C1N |
| Hazard Information | Back Directory | [Uses]
SU 3327 is a JNK inhibitor. | [Definition]
ChEBI: Halicin is a member of the class of thiadiazoles that is 1,3,4-thiadiazol-2-amine which is substituted by a (5-nitro-1,3-thiazol-2-yl)sulfanediyl group at position 5. It is a c-Jun N-terminal kinase inhibitor (IC50 = 0.7uM) and exhibits antibacterial properties. It has a role as a c-Jun N-terminal kinase inhibitor and an antibacterial agent. It is a member of thiadiazoles, a member of 1,3-thiazoles, a primary amino compound, a C-nitro compound and an organic sulfide. | [in vivo]
Halicin (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1].
Halicin (Compound 9) has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. | Animal Model: | Male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice (11-week-old ) injected with insulin[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Resulted in a statistically significant reduction in blood glucose levels.
|
| [storage]
Store at RT |
|
| Company Name: |
TCI Europe
|
| Tel: |
320-37350700 |
| Website: |
https://www.tcichemicals.com/de/de/index.html |
| Company Name: |
TCI AMERICA
|
| Tel: |
800-4238616 |
| Website: |
https://www.tcichemicals.com/en/us/index.html |
|